# Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

> **NCT03358875** · PHASE3 · COMPLETED · sponsor: **BeiGene** · enrollment: 805 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03358875
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-30
- **Primary completion:** 2021-07-15
- **Final completion:** 2024-01-18
- **Target enrollment:** 805 (ACTUAL)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03358875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03358875, "Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03358875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*